155 related articles for article (PubMed ID: 22450313)
21. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
22. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
[TBL] [Abstract][Full Text] [Related]
23. Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
Maiso P; Huynh D; Moschetta M; Sacco A; Aljawai Y; Mishima Y; Asara JM; Roccaro AM; Kimmelman AC; Ghobrial IM
Cancer Res; 2015 May; 75(10):2071-82. PubMed ID: 25769724
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
[TBL] [Abstract][Full Text] [Related]
25. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
26. Iron increases the susceptibility of multiple myeloma cells to bortezomib.
Campanella A; Santambrogio P; Fontana F; Frenquelli M; Cenci S; Marcatti M; Sitia R; Tonon G; Camaschella C
Haematologica; 2013 Jun; 98(6):971-9. PubMed ID: 23242599
[TBL] [Abstract][Full Text] [Related]
27. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
[TBL] [Abstract][Full Text] [Related]
28. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
[TBL] [Abstract][Full Text] [Related]
30. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Abeltino M; Bonomini S; Bolzoni M; Storti P; Colla S; Todoerti K; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2011 Jan; 39(1):55-65. PubMed ID: 20977926
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
35. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Kuhn DJ; Hunsucker SA; Chen Q; Voorhees PM; Orlowski M; Orlowski RZ
Blood; 2009 May; 113(19):4667-76. PubMed ID: 19050304
[TBL] [Abstract][Full Text] [Related]
36. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
37. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.
Xu D; Hu J; De Bruyne E; Menu E; Schots R; Vanderkerken K; Van Valckenborgh E
Biochem Biophys Res Commun; 2012 Nov; 428(4):518-24. PubMed ID: 23111325
[TBL] [Abstract][Full Text] [Related]
38. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
Dong H; Chen L; Chen X; Gu H; Gao G; Gao Y; Dong B
Leuk Lymphoma; 2009 Jun; 50(6):974-84. PubMed ID: 19391038
[TBL] [Abstract][Full Text] [Related]
40. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Chauhan D; Li G; Hideshima T; Podar K; Shringarpure R; Mitsiades C; Munshi N; Yew PR; Anderson KC
Oncogene; 2004 Apr; 23(20):3597-602. PubMed ID: 15094775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
